首页> 外文学位 >Expression, regulation, and function of the KIT tyrosine kinase receptor and its ligand, stem cell factor, in human epithelial ovarian cancer.
【24h】

Expression, regulation, and function of the KIT tyrosine kinase receptor and its ligand, stem cell factor, in human epithelial ovarian cancer.

机译:KIT酪氨酸激酶受体及其配体,干细胞因子在人上皮性卵巢癌中的表达,调控和功能。

获取原文
获取原文并翻译 | 示例

摘要

This Ph.D. project sought to determine the expression, regulation, and function of the KIT-SCF receptor-ligand system in human epithelia] ovarian cancer.; The expression of c-KIT and SCF in normal ovaries, in cultured ovarian surface epithelium (OSE), and in epithelia] ovarian tumors was analyzed. Normal OSE expressed SCF, but not c-KIT; however, epithelia] invaginations and inclusion cysts often expressed KIT protein. Of 15 benign ovarian tumors and tumors of low malignant potential, 87% expressed c-KIT, and 92% of these co-expressed SCF, suggesting the possibility of autocrine growth regulation. Of 35 malignant ovarian cancers, 71% expressed c-KIT (92% co-expressed SCF), with a trend for decreased c-KIT expression in advanced stage disease. Of 34 patients with malignant tumors for whom follow-up information was available (median follow-up time of 24 months), 9 had tumors that did not express c- KIT, 8 (89%) of whom have died and the remaining 1 has recurrent disease. Of the 25 patients with tumors expressing c-KIT, 56% are still alive, eight of whom have no evidence of disease. Importantly, statistical analysis indicated that patients whose tumors did not express c-KIT had a significantly shorter (p 0.05) disease-free survival time than patients who had KIT-expressing tumors.; Studies were carried out to identify intraovarian growth regulatory factors which may regulate c-KIT and SCF expression in ovarian cancer cells, and to determine whether activated KIT can affect the proliferation and survival of these cells. HEY cells, which co-expressed KIT and SCF, were treated with transforming growth factor (TGF)-α, TGF-β, and dibutyryl cyclic AMP (dbcAMP) and their cellular proliferation and expression of c- KIT and SCF were examined.; A series of transfection studies were carried out to determine if enforced c-kit expression inhuman ovarian carcinoma cells could regulate cellular proliferation. Transient transfection of c-kit into HEY cells resulted in decreased proliferation. Similarly, stable transfection of c-kit into A2780-cp cells, which do not express endogenous c-KIT, also resulted in a decreased proliferative rate. In contrast to the ovarian cancer cells, increased proliferation was documented for NIH 3T3 fibroblast cells transiently transfected with c-kit.; Together, these results suggest that the positive prognostic value of c-KIT expression in ovarian tumors is related to its negative growth regulatory function in ovarian cancer cells. (Abstract shortened by UMI.)
机译:本博士该项目试图确定KIT-SCF受体-配体系统在人上皮性卵巢癌中的表达,调控和功能。分析了正常卵巢,培养的卵巢表面上皮(OSE)和上皮]卵巢肿瘤中c- KIT 和SCF的表达。正常OSE表达SCF,但不表达c- KIT ;然而,上皮内陷和囊肿常表达KIT蛋白。在15例卵巢良性肿瘤和恶性程度低的肿瘤中,有87%的患者表达c- KIT ,其中92%的患者同时表达了SCF,这表明可能存在自分泌生长调节的可能。在35种恶性卵巢癌中,有71%的患者表达c- KIT (92%共同表达SCF),而在晚期疾病中c- KIT 表达呈下降趋势。在可获得随访信息(中位随访时间为24个月)的34例恶性肿瘤患者中,有9例不表达c- KIT 的肿瘤,其中8例(89%)已死亡,其余1例已复发。在25位表达c- KIT 的肿瘤患者中,仍有56%仍然活着,其中8位没有疾病迹象。重要的是,统计分析表明,不表达c- KIT 的患者的无病生存时间比表达KIT的患者要短得多(p <0.05)。进行了研究以确定可能调节卵巢癌细胞中c- KIT 和SCF表达的卵巢内生长调节因子,并确定活化的KIT是否会影响这些细胞的增殖和存活。共表达KIT和SCF的HEY细胞用转化生长因子(TGF)-α,TGF-β和二丁酰环AMP(dbcAMP)处理,并对其细胞增殖和c- KIT 和SCF进行了检查。进行了一系列转染研究,以确定在人卵巢癌细胞中增强的c- kit 表达是否可以调节细胞增殖。将c- kit 瞬时转染到HEY细胞中导致增殖减少。同样,将c- kit 稳定转染到不表达内源性c- KIT 的A2780-cp细胞中,也会导致增殖率降低。与卵巢癌细胞相反,用c- kit 瞬时转染的NIH 3T3成纤维细胞具有增加的增殖能力。总之,这些结果表明,c- KIT 表达在卵巢肿瘤中的阳性预后价值与其在卵巢癌细胞中的负生长调节功能有关。 (摘要由UMI缩短。)

著录项

  • 作者

    Tonary, Angela Marie.;

  • 作者单位

    University of Ottawa (Canada).;

  • 授予单位 University of Ottawa (Canada).;
  • 学科 Health Sciences Obstetrics and Gynecology.
  • 学位 Ph.D.
  • 年度 2001
  • 页码 180 p.
  • 总页数 180
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 妇幼卫生;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号